PepsiCo Just Reported Earnings. Here's What Investors Need to Know.
2026-10-09 14:26
•Jeremy Bowman •The Motley Fool
••••••• • Axe Cap view
PepsiCo’s Mixed Signals: What SA Investors Should Watch
PepsiCo’s latest results offer a defensive dividend angle but reveal North American headwinds that deserve attention.
PepsiCo’s recent earnings beat surprised on the upside with 3.1% organic growth, mainly driven by international markets. However, a cut in full-year earnings guidance signals troubles lurking, particularly in its core North American beverage and snack segments. The rise of GLP-1 weight loss drugs has altered consumer habits, making sugary drinks and snacks less attractive — a trend that’s tough to reverse quickly. For investors focused on South Africa, the direct exposure to PepsiCo is limited, but it’s worth noting that international consumer preferences can shift currency flows, potentially influencing the USD/ZAR pair. The rand has seen relief in USD terms partly due to global dollar softness, but if US consumer weakness deepens, rand-linked exporters may feel the squeeze too. PepsiCo’s 4.6% dividend yield and modest valuation around 15 times earnings offset some concerns, offering a cushion for income-minded investors. Still, if the shift in US consumer behavior is bigger or longer-lasting than expected, PepsiCo’s turnaround could stall. this is just our opinion and not financial advice
Watch PepsiCo closely for a better entry point — its dividend yield is appealing but hold off buying outright until the North American recovery looks clearer. In the interim, consider the rand’s sensitivity to US consumer trends by tracking USD/ZAR moves.
- USD/ZAR
- PepsiCo (PEP)
- Prolonged weakness in US consumer spending
- Accelerating impact of GLP-1 drugs on snack and beverage demand
5/10
PepsiCo beat Q3 earnings expectations with 3.1% organic revenue growth and a 3.7% stock price increase, despite cutting full-year EPS guidance to 2.5%-3.5%. The company faces challenges in North America beverages and snacks due to GLP-1 drug impacts and consumer pushback, but international segments remain strong. With a 4.6% dividend yield and P/E of 15, the stock may appeal to defensive dividend investors seeking recovery potential.
Our take is based on reporting first published by The Motley Fool.